Trial Profile
Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cilostazol (Primary)
- Indications Coronary artery disease; Myocardial infarction
- Focus Therapeutic Use
- 07 Dec 2014 Modified secondary endpoints, inclusion - exclusion criteria and changed planned patient number from 60 to 300, as reported by ClinicalTrials.gov.
- 29 Jul 2014 New trial record